Close

Search

Search Menu
Photonics Media Photonics Buyers' Guide Photonics EDU Photonics Spectra BioPhotonics EuroPhotonics Industrial Photonics Photonics Showcase Photonics ProdSpec Photonics Handbook
More News
share
Email Facebook Twitter Google+ LinkedIn Comments

Bayer HealthCare

BioPhotonics
Jul 2009
Bayer HealthCare of Berlin has entered into a strategic agreement to transfer its hematological oncology portfolio to Genzyme Corp. of Cambridge, Mass. This includes granting the American company exclusive worldwide licenses for several of the products in the portfolio. In return, the German company will receive milestone payments and royalties, which could add up to as much as $650 million.

Bayer HealthcareBiophotonicshematological oncologyNews & Features

Comments
Terms & Conditions Privacy Policy About Us Contact Us
back to top

Facebook Twitter Instagram LinkedIn YouTube RSS
©2017 Photonics Media
x Subscribe to BioPhotonics magazine - FREE!